BWAY trades 7.5% below Wall Street's consensus target of $16.00.
Last 12 months price action with 12-month analyst target path
The base valuation assumes BWAY achieves its forward estimates and maintains a stable P/E multiple of 49.1x. This scenario reflects the blended consensus of 6 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of June 21, 2026, BrainsWay Ltd. (BWAY) has a Wall Street consensus price target of $16.00, based on estimates from 6 covering analysts. With the stock currently trading at $14.89, this represents a potential upside of +7.5%. The company has a market capitalization of $584M.
Analyst price targets range from a low of $15.00 to a high of $17.00, representing a 13% spread in expectations. The median target of $16.00 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Buy, with 5 analysts rating the stock as a Buy or Strong Buy,1 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, BWAY trades at a trailing P/E of 41.4x and forward P/E of 49.1x. Analysts expect EPS to grow -34.4% over the next year.
Our proprietary valuation model, which blends historical multiples with forward estimates, suggests a base-case price target of $4.46, with bear and bull scenarios of $2.81 and $5.87 respectively. Model confidence stands at 56/100, reflecting moderate uncertainty in projections.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
STIMNeuronetics, Inc. | $86M | $1.23 | $8.00 | +550.4% | Buy | — | 7 |
NVCRNovoCure Limited | $1.6B | $14.28 | $33.00 | +131.1% | Buy | — | 15 |
LIVNLivaNova PLC | $4.3B | $78.50 | $79.86 | +1.7% | Buy | 18.5x | 14 |
GKOSGlaukos Corporation | $7.6B | $130.68 | $151.25 | +15.7% | Buy | — | 24 |
ELMDElectromed, Inc. | $320M | $38.68 | $38.00 | -1.8% | Buy | 31.8x | 5 |
ABTAbbott Laboratories | $153.7B | $88.38 | $127.46 | +44.2% | Buy | 16.1x | 41 |
MDTMedtronic plc | $101.9B | $79.34 | $95.80 | +20.7% | Buy | 13.3x | 51 |
BSXBoston Scientific Corporation | $67.3B | $45.29 | $82.90 | +83.0% | Buy | 13.5x | 44 |
HOLXHologic, Inc. | $17.0B | $76.01 | $78.69 | +3.5% | Hold | 17.2x | 42 |
INVAInnoviva, Inc. | $1.7B | $22.49 | $37.00 | +64.5% | Buy | 6.3x | 10 |
Quick answers to the most common questions about buying BWAY stock.
The consensus price target for BWAY is $16, close to the current price of $14.89 (7.5% implied move). Based on 6 analyst estimates, the stock appears fairly valued near current levels.
BWAY has a consensus rating of "Buy" based on 6 Wall Street analysts. The rating breakdown is predominantly bullish, with 5 Buy/Strong Buy ratings. The consensus 12-month price target of $16 implies 7.5% upside from current levels.
At a forward P/E of 49.0933x, BWAY trades at a premium valuation. The consensus price target of $16 (7.5% upside) suggests analysts may view current valuations as stretched.
The most bullish Wall Street analyst has a price target of $17 for BWAY, while the most conservative target is $15. The consensus of $16 represents the median expectation. Our quantitative valuation model projects a bull case target of $6 based on optimistic growth and margin assumptions. These targets typically reflect 12-month expectations.
BWAY is moderately covered, with 6 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 5 have Buy ratings, 1 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month BWAY stock forecast based on 6 Wall Street analysts shows a consensus price target of $16, with estimates ranging from $15 (bear case) to $17 (bull case). The median consensus rating is "Buy". Our proprietary valuation model produces a base case fair value of $4, with bear/bull scenarios of $3/$6.
Our quantitative valuation model calculates BWAY's fair value at $4 (base case), with a bear case of $3 and bull case of $6. The model uses discounted cash flow analysis, historical growth rates, and margin mean-reversion to project FY+2 earnings, then applies an appropriate P/E multiple. The model confidence score is 56/100.
BWAY trades at a forward P/E ratio of 49.1x based on next-twelve-months earnings estimates compared to a trailing P/E of 41.4x. The higher forward P/E suggests near-term earnings pressure. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
BWAY appears fairly valued according to analysts, with a "Buy" rating and minimal upside to the $16 target. Consider your investment thesis and risk tolerance. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
BWAY analyst price targets range from $15 to $17, a 13% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $16 consensus represents the middle ground. Our model's $3-$6 range provides an independent fundamental perspective.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.